首页> 外国专利> Hydroxymethylglutarylcoenzyme A (HMG CoA) reductase inhibitor (or a statin) and a fibrate in a single effective oral dosage form to treat dyslipidaemia and dyslipoproteinaemia

Hydroxymethylglutarylcoenzyme A (HMG CoA) reductase inhibitor (or a statin) and a fibrate in a single effective oral dosage form to treat dyslipidaemia and dyslipoproteinaemia

机译:单一有效口服剂型中的羟甲基戊二酰辅酶A(HMG CoA)还原酶抑制剂(或他汀类药物)和贝特类药物治疗血脂异常和血脂蛋白异常

摘要

Described is an orally administered pharmaceutical composition for the treatment of elevated levels of cholesterol and related conditions comprising a statin and fenofibrate in the form of microparticles of solid fenofibrate that are stabilized by phospholipid as a surface active substance, wherein a therapeutically effective amount of the composition provides the statin and a quantity of fenofibrate to a fasted human patient that is greater than 80 % of the quantity of fenofibrate provided by the same amount of the composition when administered to the same patient who has been fed a high fat meal.
机译:描述了一种用于治疗胆固醇水平升高和相关病症的口服药物组合物,其包含他汀和非诺贝特的固体非诺贝特微粒形式,其通过磷脂作为表面活性物质而稳定,其中治疗有效量的该组合物向禁食的人类患者提供的他汀类药物和非诺贝特的量大于当给已经喂食高脂肪餐的同一位患者给药时由相同量的组合物提供的非诺贝特量的80%。

著录项

  • 公开/公告号NZ527408A

    专利类型

  • 公开/公告日2005-04-29

    原文格式PDF

  • 申请/专利权人 SKYEPHARMA CANADA INC;

    申请/专利号NZ20010527408

  • 申请日2001-04-20

  • 分类号A61K9/14;A61K31/366;A61K31/365;A61K45/06;A61K31/66;A61K31/505;A61K31/44;A61K31/405;A61K31/40;A61K31/22;A61K9/16;

  • 国家 NZ

  • 入库时间 2022-08-21 22:16:53

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号